Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy
February 03, 2021 08:55 ET
|
Telo Genomics Corp.
TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has entered into a consulting agreement with the...
Telo Genomics Presents at ASH 2020 The Results of Hodgkin’s Lymphoma Clinical Study
December 09, 2020 09:00 ET
|
Telo Genomics Corp.
TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has presented the results of its Hodgkin’s lymphoma...
Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patients and Patients That Progressed to Active Multiple Myeloma
November 16, 2020 11:13 ET
|
Telo Genomics Corp.
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept...
Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease
November 11, 2020 12:26 ET
|
Telo Genomics Corp.
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has received final approval and grant of three of its pending...
Telo Genomics Announces Warrant Exercise Agreement
October 21, 2020 08:30 ET
|
Telo Genomics Corp.
TORONTO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (OTC: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has engaged Leede Jones Gable Inc. and Mackie...
Telo Genomics Announces that Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within ASH 2020 Proceedings
October 13, 2020 09:15 ET
|
Telo Genomics Corp.
TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that its abstract submitted to the American Society of Hematology (ASH)...
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow
September 14, 2020 09:15 ET
|
Telo Genomics Corp.
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with...
Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic
December 20, 2019 09:00 ET
|
Telo Genomics Corp.
TORONTO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in...
Telo Genomics Announces Grant of Stock Options
November 28, 2019 08:45 ET
|
Telo Genomics Corp.
TORONTO, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) announces that it has granted incentive stock options to various directors, officers, employees...
Telo Genomics Completes Oversubscribed $1.735 Million Financing, Debt Settlement and Share Consolidation
November 25, 2019 08:45 ET
|
Telo Genomics Corp.
TORONTO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has closed its previously announced oversubscribed $1,735,500...